Navigation Links
For Osteoporosis and Osteopenia, Clinical Data and Thought Leaders' Opinions Indicate that AMG-785/CDP-7851 and Odanacatib Have Advantages Over Alendronate
Date:4/4/2013

BURLINGTON, Mass., April 4, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that surveyed U.S. and European primary care physicians (PCPs) agree that efficacy on hip fracture risk reduction is one of the attributes that most influences their decisions regarding prescribing in osteoporosis and osteopenia. Clinical data and the opinions of interviewed thought leaders indicate that Amgen/UCB's AMG-785/CDP-7851 and Merck's odanacatib have advantages over patient share leader alendronate (Merck's Fosamax, Teijin's Bonalon, generics) on this attribute.

(Logo: http://photos.prnewswire.com/prnh/20130103/MM36784LOGO)

The DecisionBase 2013 report entitled Emerging Therapies AMG-785/CDP-781 and Odanacatib Are Poised to Overtake Teriparatide's Status as the Clinical Gold Standard also finds that, based on clinical data and the opinions of interviewed thought leaders, teriparatide (Eli Lilly's Forteo/Forsteo, Asahi Kasei's Teribone) is Decision Resources' current proprietary clinical gold-standard therapy for osteoporosis and osteopenia. Teriparatide has the strongest clinical profile among key marketed products that treat osteoporosis and osteopenia. However, AMG-785/CDP-7851 is expected to displace teriparatide and will earn proprietary clinical gold-standard status for osteoporosis and osteopenia in 2021, following its launch for the indication in 2017. AMG-785/CDP-7851 has competitive advantages in safety and tolerability as well as delivery over teriparatide and advantages in efficacy and safety over the current standard of care, alendronate.

"It is important to note, however, that AMG-785/CDP-7851 is considered only marginally better than odanacatib, which fa
'/>"/>

SOURCE Decision Resources
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Active Lifes BioDent Reference Point Indenter Validated in Study Published by Osteoporosis Medical Opinion Leaders
2. Unigenes Phase 2 Study of Oral PTH for the Treatment of Osteoporosis in Postmenopausal Women Featured in Bone
3. Osteoporosis Drug Market- Global And China Market Analysis, Size, Trends And Forecast (2010-2015)
4. Array BioPharma Announces Updates on ARRY-520 Clinical Data at the 2013 International Myeloma Workshop
5. VG Life Sciences Reports Positive Safety Results from Second Cohort Enrollment in Solid Tumor Clinical Trial
6. NewLink Genetics Presents Preclinical Data on NLG919, a New Drug Candidate from a Novel Class of IDO Pathway Inhibitors for the Treatment of Cancer
7. NorDx Enhances Clinical Laboratory Diagnostic Services with State-of-the-Art Technology
8. AG Mednet and Japans Biovisiq Bring Zero-Delay Clinical Trial Solutions to Asian Pharmaceutical Market
9. N30 Pharma Announces Presentation of Preclinical Data at the Basic Science Meeting of the European Cystic Fibrosis Society
10. Inovio Collaborator ChronTech Reports Interim Phase II Clinical Study Results from ChronVac-C Vaccine for Hepatitis C Infection
11. DelMar Pharmaceuticals to Present Clinical Data from VAL-083 Brain Cancer Trial at the American Association of Cancer Research Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... , July 30, 2014  El Camino Hospital, a ... care, is utilizing the Leaf Patient Monitoring system to ... and movement of patients susceptible to bed sores. ... month-long, 138-patient study of the system, which showed dramatic ... Turning patients regularly is the one of the most ...
(Date:7/30/2014)... , July 30, 2014  InnoPharma, Inc. today ... 10mg/vial (the generic equivalent of Zyprexa® injection), in Canada.  ... and disturbed behaviors in patients with schizophrenia or bipolar ... generic injectable drug, InnoPharma has entered into an agreement ... Canada will make, use, sell, market and distribute ...
(Date:7/30/2014)... Cynosure, Inc. (NASDAQ: CYNO ... non-invasive and minimally invasive applications, today announced that the Board ... and Chief Financial Officer Timothy W. Baker to ... will continue to serve as CFO and will take the ... Chairman and Chief Executive Officer. "Tim has ...
Breaking Medicine Technology:El Camino Hospital Utilizes Cutting-Edge Leaf Patient Monitor System to Help Reduce Risk of Pressure Ulcers 2El Camino Hospital Utilizes Cutting-Edge Leaf Patient Monitor System to Help Reduce Risk of Pressure Ulcers 3InnoPharma Announces Launch of Olanzapine for Injection, 10mg/vial in Canada 2Cynosure Appoints Chief Operating Officer and Chief Financial Officer Timothy W. Baker as President 2
... ST. LOUIS, Dec. 21, 2010 Pepex Biomedical, ... solution for insulin dependent diabetics which will combine ... sufferers worldwide.  The company is developing a complete ... testing of blood glucose levels and insulin delivery, ...
... Reportlinker.com announces that a new market research report ... Cyclohexane: 2010 World Market Outlook And Forecast ... market research features all the important sides of ... focusing on the world market, regional and countries, ...
Cached Medicine Technology:Pepex™ Unveils Development of First All-In-One Blood Glucose Meter 2Reportlinker Adds Cyclohexane: 2010 World Market Outlook And Forecast 2
(Date:7/30/2014)... The family of a Vermont man ... Xarelto lawsuit ( http://www.xareltolawsuitcenter.com/ ) alleging his death ... reports. According to the complaint, which was filed in ... July 25th, the decedent had been taking Xarelto for ... bleed that ultimately led to his death on August ...
(Date:7/30/2014)... (PRWEB) July 30, 2014 Hamilton ... opening of its new Carmel office on July 30th. ... will finally be moving to the state-of-the-art suite, located ... and innovative space will allow for one-on-one patient comfort, ... surgery experience. , Dr. Hamilton’s new office-suite will ...
(Date:7/30/2014)... 2014 DRE Medical — a leading ... launch of its Medical Trade Shows & Conventions ... professionals and equipment vendors. , The calendar is a ... the United States and around the world. Hundreds of ... number is always growing. , Information listed on each ...
(Date:7/30/2014)... The Technology Association of Georgia in ... (B&TA), today issued its final call for applications and ... companies have until August 29th 2014 to be considered ... selected by the Excalibur Judging Committee. Companies selected as ... judges for interviewing process. , The TAG Excalibur ...
(Date:7/30/2014)... (PRWEB) July 30, 2014 LTC Consumer, an ... long term care insurance, features an Instant Quote tool on ... and co-founder of LTC Consumer. Quotes are free and unlimited. ... click in only seven areas – including age, gender, and ... screen within seconds (you don’t need to enter any contact ...
Breaking Medicine News(10 mins):Health News:Xarelto Lawsuit Alleges Man’s Death from Uncontrollable Brain Bleeding Was Caused by Xarelto, Bernstein Liebhard LLP Reports 2Health News:Xarelto Lawsuit Alleges Man’s Death from Uncontrollable Brain Bleeding Was Caused by Xarelto, Bernstein Liebhard LLP Reports 3Health News:Hamilton Facial Plastic Surgery Opens New Carmel Office 2Health News:DRE Launches Online Interactive Medical Trade Show Calendar 2Health News:Last Call for TAG 2014 Excalibur Awards Nominations and Applications 2Health News:Last Call for TAG 2014 Excalibur Awards Nominations and Applications 3Health News:LTC Consumer Launches Online Tool for Getting Instant Long Term Care Insurance Estimates 2
... acclaimed as the "gold-standard" amongst researchers for scientific studies. ... on the other, has also questioned the worth of ... complementary and alternative medicine (CAM) practices. Majority of CAM ... cure. , ,The question arises as to whether ...
... Diabetes is the leading cause of end-stage kidney disease ... or a kidney transplant for survival. // ,A ... and the University of Heidelberg has proven that a ... kidney failure or "end-stage renal disease." ,The ...
... are facing one of the worst gastroenteritis epidemics that ... with patients coming// in droves for relief. The infection ... for a few days but seldom endangers life. ... Montreal area have reported the viral outbreak. Dr. Joseph ...
... have been created from blue green algae by scientists with ... on properties and actions of enzymes is also taken into ... possible to produce enough of the promising drugs for use ... the cover of the January issue of the journal ACS ...
... recent studies have shown that the chance of developing it ... the chances of surviving it, also depend on the same ... 50,000 pounds behind a study to be carried out by ... cancer survivors aged above fifty and with a BMI (Body ...
... detect infection of drug resistant forms of HIV even when ... the Duke University Medical Center. ,This new test ... in small amounts contrary to other tests that detect drug-resistant ... bloodstream. ,This new test is expected to be ...
Cached Medicine News:Health News:Is Evidence-based Medicine Enough to Support Additional Research in Alternative Medicine? 2Health News:A Gene Associated With Severe Kidney Failure in Diabetes Found 2Health News:Anti Cancer Drug from Blue Green Algae 2
... Enzyme-linked immunosorbent assay method for ... autoantibodies to myeloperoxidase in human serum. ... can be used as an aid ... and other conditions associated with elevated ...
... of this Enzyme ImmunoAssay (EIA) is as ... immobilised on a 96 well microtiter plate. ... washing, the trapped molecule is covalently linked ... groups. After washing and denaturing treatment, Angiotensin ...
... determination of Ang II is ... the pharmacological effect and efficiency ... angiotensin converting enzyme inhibitors (ACE ... antagonists as well as for ...
Anti-RSV IgA Assay (ELISA)....
Medicine Products: